Blood Cancer Journal

Scope & Guideline

Advancing knowledge in blood cancer research.

Introduction

Delve into the academic richness of Blood Cancer Journal with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN2044-5385
PublisherSPRINGERNATURE
Support Open AccessYes
CountryUnited States
TypeJournal
Convergefrom 2011 to 2024
AbbreviationBLOOD CANCER J / Blood Cancer J.
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressCAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND

Aims and Scopes

The Blood Cancer Journal aims to advance the understanding of hematological malignancies through innovative research and clinical insights. Its focus encompasses a diverse range of topics within blood cancers, emphasizing the need for precision in diagnosis and treatment.
  1. Hematological Malignancies Focus:
    The journal primarily addresses various types of blood cancers, including multiple myeloma, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and lymphomas. This focus allows for a comprehensive understanding of disease mechanisms and treatment outcomes.
  2. Clinical Research and Trials:
    A significant emphasis is placed on clinical trials, providing insights into new therapies, treatment regimens, and patient outcomes. The journal publishes studies that evaluate novel drug combinations and treatment strategies, contributing to evidence-based practice.
  3. Genomic and Molecular Insights:
    The journal highlights research that delves into the genomic and molecular landscape of hematological malignancies. This includes studies on mutations, gene expression profiles, and the impact of genomic alterations on prognosis and treatment response.
  4. Therapeutic Innovations:
    Research on emerging therapies, including CAR-T cell therapy, bispecific antibodies, and targeted therapies, is a core area. The journal aims to disseminate findings that may lead to improved treatment protocols and patient outcomes.
  5. Patient-Centric Studies:
    The journal also focuses on patient-reported outcomes and the quality of life of individuals with blood cancers, addressing the psychosocial aspects of treatment and survivorship.
The Blood Cancer Journal reflects dynamic trends in research, showcasing emerging themes that are gaining traction in the field of hematologic malignancies. These trends indicate a shift towards more personalized and innovative approaches to understanding and treating blood cancers.
  1. Precision Medicine and Genomics:
    There is a surge in studies focusing on precision medicine, highlighting the importance of genetic profiling and molecular characterization of tumors. This trend reflects the move towards individualized treatment strategies tailored to the genetic makeup of each patient’s cancer.
  2. Immunotherapy Advances:
    Research on immunotherapy, including CAR-T cell therapy and bispecific antibodies, is increasingly prevalent. This reflects a broader shift in the treatment landscape, with a focus on harnessing the immune system to combat hematologic malignancies.
  3. Real-World Evidence and Patient Outcomes:
    Emerging studies are emphasizing real-world evidence and patient-reported outcomes, showcasing the importance of understanding treatment effectiveness and quality of life in diverse patient populations.
  4. Multi-Omics Approaches:
    The application of multi-omics strategies (genomics, transcriptomics, proteomics) to better understand disease mechanisms and treatment responses is on the rise, indicating a trend towards more comprehensive research methodologies.
  5. Health Disparities and Access to Care:
    An increasing number of studies are addressing health disparities and access to care in hematological malignancies, highlighting the need for equitable treatment options and outcomes across different demographics.

Declining or Waning

As the Blood Cancer Journal evolves, certain themes that were once prevalent appear to be declining in prominence. This could reflect shifts in research priorities, advances in treatment modalities, or the natural progression of scientific inquiry.
  1. Traditional Chemotherapy Studies:
    There is a noticeable decrease in studies focusing exclusively on traditional chemotherapy regimens. As newer targeted therapies and immunotherapies gain traction, research on older treatment methods is becoming less common.
  2. Efficacy of Standardized Treatment Protocols:
    Research on standardized treatment protocols, which previously dominated discussions, is becoming less frequent. The focus is shifting towards personalized medicine approaches that consider individual genetic profiles and responses.
  3. Basic Biological Mechanisms:
    While foundational studies on the biology of hematological malignancies remain important, there seems to be a waning interest in purely basic science articles that do not directly translate into clinical applications or therapeutic advancements.

Similar Journals

Journal of Hematology

Pioneering Discoveries in Blood Health
Publisher: ELMER PRESS INCISSN: 1927-1212Frequency: 4 issues/year

The Journal of Hematology, published by ELMER PRESS INC, serves as a pivotal platform for disseminating cutting-edge research in the field of hematology. With an ISSN of 1927-1212 and an E-ISSN of 1927-1220, this journal is committed to advancing scientific knowledge and clinical practice through high-quality peer-reviewed articles encompassing all aspects of blood disorders, from basic science to health policy implications. While the journal currently operates under a traditional access model, it nonetheless prioritizes the rapid publication of significant findings, ensuring that researchers, clinicians, and students have timely access to the latest advancements in hematological research. Positioned to bridge gaps in knowledge and foster collaboration among scholars worldwide, the Journal of Hematology is an essential resource for anyone invested in this vital area of medicine.

LEUKEMIA

Advancing the Frontiers of Hematology and Oncology
Publisher: SPRINGERNATUREISSN: 0887-6924Frequency: 12 issues/year

LEUKEMIA, published by SpringerNature, is a premier journal in the field of hematology and oncology, with ISSN 0887-6924 and E-ISSN 1476-5551. Established in 1987, this esteemed publication serves as a critical platform for disseminating groundbreaking research and comprehensive reviews on the pathophysiology, diagnosis, and treatment of leukemia and related hematological disorders. With a distinguished impact, it holds a top-tier status in several categories, including Q1 rankings in Anesthesiology and Pain Medicine, Cancer Research, Hematology, and Oncology for 2023. The journal is globally recognized for its rigorous peer-review process and is highly regarded among academia, evidenced by its impressive Scopus rankings—7th in Hematology and 24th in Oncology. Researchers, clinicians, and students alike will benefit from the rich content that this journal offers, making it an invaluable resource in the fight against leukemia. The main objective of LEUKEMIA is to advance knowledge and encourage further innovations within the field, ensuring that vital insights reach practitioners and researchers around the world.

Indian Journal of Hematology and Blood Transfusion

Illuminating the Path in Hematology and Transfusion Practices
Publisher: SPRINGER INDIAISSN: 0971-4502Frequency: 4 issues/year

Indian Journal of Hematology and Blood Transfusion, published by SPRINGER INDIA, serves as a leading platform for disseminating original research, reviews, and case studies in the field of hematology. With an ISSN of 0971-4502 and E-ISSN 0974-0449, this journal has been instrumental in advancing knowledge from 2000 to 2024, providing insights into critical issues surrounding blood disorders and transfusion practices. Currently ranked in the Q3 category for Hematology for 2023, it reflects a commitment to high-quality scientific content amidst a competitive landscape where it ranks 97/137 in Scopus for Medicine - Hematology, placing it in the 29th percentile of its peers. The journal primarily addresses a diverse readership, including researchers, healthcare professionals, and students, aiming to foster innovation and collaboration within the field. Although it operates under a subscription model, access options for individual articles and institutional subscriptions ensure that valuable research is disseminated widely to enhance medical practice and education in hematology.

Iraqi Journal of Hematology

Unveiling Breakthroughs in Blood Disorders
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 2072-8069Frequency: 2 issues/year

Iraqi Journal of Hematology is a prominent peer-reviewed open-access journal dedicated to advancing the field of hematology. Published by Wolters Kluwer Medknow Publications, this journal provides a platform for researchers, professionals, and students to share cutting-edge findings and developments in various aspects of hematology, including blood diseases, diagnostics, and innovative treatments. Since its transition to open access in 2016, the journal has significantly increased its reach, allowing for wider dissemination of critical research to a global audience. With an ISSN of 2072-8069 and an E-ISSN of 2543-2702, the Iraqi Journal of Hematology strives to adhere to the highest scholarly standards and plays a vital role in the ongoing discourse in hematological research. Researchers are encouraged to contribute to this essential resource for the scientific community, contributing to the advancement of knowledge that ultimately improves patient care and treatment outcomes.

Blood Cancer Discovery

Exploring Innovations in Oncology and Beyond
Publisher: AMER ASSOC CANCER RESEARCHISSN: 2643-3230Frequency: 6 issues/year

Blood Cancer Discovery is a premier academic journal published by the American Association for Cancer Research, dedicated to advancing the understanding of hematologic malignancies through cutting-edge research in the fields of oncology, biochemistry, and molecular biology. With an impressive impact factor and recognition as a Q1 journal across multiple disciplines, including cancer research and hematology, Blood Cancer Discovery serves as an essential platform for scholars and practitioners alike, facilitating impactful discourse and dissemination of pioneering findings. This open-access journal, established within the vibrant academic landscape of the United States, aims to bridge gaps in research and foster collaborations to ultimately enhance patient outcomes. Its Scopus rankings demonstrate its vital role in the critical advancement of cancer research and therapeutic development. By inviting contributions from a diverse range of disciplines, Blood Cancer Discovery is poised to drive innovation and inspire future advancements in understanding blood cancers.

CANCER JOURNAL

Transforming Cancer Treatment Through Groundbreaking Research.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1528-9117Frequency: 6 issues/year

CANCER JOURNAL is a leading peer-reviewed publication dedicated to the dissemination of innovative research in the fields of cancer research and oncology. Published by Lippincott Williams & Wilkins, this journal serves as an essential resource for researchers, clinicians, and students seeking to advance their understanding of cancer mechanisms, treatment strategies, and patient care. With an ISSN of 1528-9117 and an E-ISSN of 1540-336X, it boasts a respectable 2023 Q2 category ranking in both Cancer Research and Oncology, reflecting its impactful contributions to the scientific community. Although it currently does not offer open access, the journal's rigorous peer-review process ensures the publication of high-quality, relevant studies that stimulate further investigation and collaboration among professionals. Since its inception, the journal has evolved through several converged years, maintaining a steadfast commitment to addressing the complexities of cancer biology and treatment. At its core, CANCER JOURNAL aims to foster advancements in oncology, making it a vital platform for sharing pivotal findings that could transform cancer research and therapeutic practices.

Oncology Research and Treatment

Shaping the landscape of cancer treatment and research.
Publisher: KARGERISSN: 2296-5270Frequency: 10 issues/year

Oncology Research and Treatment, published by KARGER, is a highly regarded academic journal dedicated to advancing the field of oncology through rigorous research and clinical insights. With a history spanning from 1978 to 1997 and continuing from 2013 to 2024, this journal provides a vital platform for researchers and professionals in cancer research, hematology, and related disciplines. Though currently listed in the Q3 tier of 2023 for Cancer Research, Hematology, and Oncology, its growing readership and open access policy enhance its visibility and impact within the scientific community. Based in Switzerland, the journal features diverse access options, reflecting the global importance of oncology research. With a focus on innovative treatments and the latest methodologies, Oncology Research and Treatment plays a crucial role in fostering collaboration and dialogue among researchers, professionals, and students alike, helping to shape the future of cancer care and management.

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

Enhancing understanding, improving outcomes for young patients.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1077-4114Frequency: 8 issues/year

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, published by Lippincott Williams & Wilkins, serves as a vital platform for the dissemination of cutting-edge research and insights in the fields of pediatric hematology and oncology. Since its inception in 1979, the journal has maintained a commitment to advancing knowledge through peer-reviewed articles that contribute to the understanding and treatment of blood disorders and cancers in children. With an impact factor reflective of its academic contributions, the journal is positioned in the Q3 quartile across key medical categories — Hematology, Oncology, and Pediatrics, Perinatology and Child Health — indicating its relevance and influence in the field. While it does not currently offer open access options, the journal remains a crucial resource for researchers, clinicians, and students dedicated to improving pediatric care and outcomes. Researchers are encouraged to contribute to this esteemed journal as it seeks to bridge the gap between clinical practice and research, fostering innovation and improved quality of life for young patients affected by hematologic and oncologic conditions.

PEDIATRIC HEMATOLOGY AND ONCOLOGY

Fostering dialogue in the realm of child health and treatment.
Publisher: TAYLOR & FRANCIS INCISSN: 0888-0018Frequency: 8 issues/year

Pediatric Hematology and Oncology, published by Taylor & Francis Inc, serves as a vital platform dedicated to the fields of hematology, oncology, and pediatrics, providing a comprehensive avenue for the dissemination of scholarly research and clinical advancements. With an ISSN of 0888-0018 and an E-ISSN of 1521-0669, this journal has successfully converged its expertise over the years from 1984 to 2024. Ranked in the Q3 category for Hematology and Oncology, alongside a Q2 ranking in Pediatrics, Perinatology, and Child Health (2023), it engages a diverse readership comprising researchers, healthcare professionals, and students eager to explore groundbreaking studies in child health and treatment methodologies. While it currently does not offer Open Access options, the journal is widely cited and recognized, particularly in its specialized fields, fostering a rich environment for dialogue and innovation in the management of pediatric hematological and oncological disorders. The journal is based in the United Kingdom at 530 Walnut Street, Ste 850, Philadelphia, PA 19106, making it an essential resource for those pursuing excellence in pediatric medical research.

Egyptian Journal of Haematology

Empowering Hematologists with Cutting-Edge Research
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 1110-1067Frequency: 4 issues/year

The Egyptian Journal of Haematology, published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, stands as a pivotal resource in the field of hematology, particularly within the context of Egypt and the broader Middle Eastern region. This journal is dedicated to disseminating high-quality research that explores the latest advancements in blood disorders, hematologic malignancies, and transfusion medicine. With a focus on original research, case studies, and reviews, it aims to provide a comprehensive platform for hematologists, researchers, and healthcare professionals to enhance their understanding and management of hematological conditions. Although it is not an open-access journal, the rigorous peer-review process ensures that only the most impactful studies are published, contributing to the journal's reputation in the academic community. The Egyptian Journal of Haematology serves as an essential tool for advancing knowledge, improving clinical outcomes, and fostering collaboration among experts in the field.